Spine arthroplasty--replacing either the entire disc or simply the nucleus--is one of the most promising new therapies to treat patients with herniated discs and degenerative disc disease. But the technology has had a rocky history: rushed into patients too soon, without proper clinical trials, say critics, disc replacement languished in Europe and took a long time to attract interest in the US. Moreover, first generation arthroplasty products, most notably discs, had several drawbacks that limited adoption--some were very hard to implant, for example, while others were too stiff and tended to extrude. Companies like Disc Dynamics hope to ride the wave of interest in disc and nucleus replacement as it develops new technology that is both superior to first generation products and backed by the proper kinds of clinical studies.
by David Cassak
Most new medical device technology follows a predictable development path, beginning with a designing physician or engineer, through an early phase of investigation and early adopters, to a broader roll-out...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
Annual survey of patients and professionals shows how attitudes to health system transformation are evolving and what stakeholders are demanding as acceptance of AI tools accelerates.
BioWales in London 2025 showcased the efforts healthtech innovators are making to meet investors on their own turf, illustrating changing attitudes and evolving needs.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.
Almost halfway through 2025, and financing for European biotech could be described as challenging. Market volatility, geopolitical instability and trade barriers all loom large in biotech CEO minds when pitching for funding. In Vivo talked to biotechs and investors to gain a realistic view of the current market for company funding so far this year.
From chemical engineering to cancer innovation, AbbVie's rising oncology leader is advancing next-generation ADCs to tackle difficult-to-treat tumors with a patient-centered approach.
Mini-profiles of five synthetic biology companies and their leaders from SynBioBeta 2025 reveal how AI integration, data-driven platforms and interdisciplinary teams are revolutionizing drug discovery and manufacturing.